key: cord-0880150-imxhxr2a authors: Goswami, Ria; Russell, Veronica S.; Tu, Joshua J.; Hughes, Philip; Kelly, Francine; Langel, Stephanie N.; Steppe, Justin; Palmer, Scott M.; Haystead, Timothy; Blasi, Maria; Permar, Sallie R. title: Oral Hsp90 inhibitor, SNX-5422, attenuates SARS-CoV-2 replication and dampens inflammation in airway cells date: 2021-02-23 journal: bioRxiv DOI: 10.1101/2021.02.23.432479 sha: e8436440082c9a1cab46fe4c5bbc14110d0131dd doc_id: 880150 cord_uid: imxhxr2a Currently available SARS-CoV-2 therapeutics are targeted towards moderately to severely ill patients and require intravenous infusions, with limited options for exposed or infected patients with no or mild symptoms. While vaccines have demonstrated protective efficacy, vaccine hesitancy and logistical distribution challenges will delay their ability to end the pandemic. Hence, there is a need for rapidly translatable, easy-to-administer-therapeutics, that can prevent SARS-CoV-2 disease progression, when administered in the early stages of infection. We demonstrate that an orally bioavailable Hsp90 inhibitor, SNX-5422, currently in clinical trials as an anti-cancer therapeutic, inhibits SARS-CoV-2 replication in vitro at a high selectivity index. SNX-5422 treatment of human primary airway epithelial cells dampened expression of inflammatory pathways associated with poor SARS-CoV-2 disease outcomes. Additionally, SNX-5422 interrupted expression of host factors that are crucial for SARS-CoV-2 replication machinery. Development of SNX-5422 as SARS-CoV-2-early-therapy will dampen disease severity, resulting in better clinical outcomes and reduced hospitalizations. In addition to developing antivirals targeting specific viral proteins , there has been a 157 growing effort in developing therapeutics targeting host proteins exploited by viruses for 158 their replication or implicated in viral pathogenesis (Nitulescu et al., 2020) . As such 159 therapeutics can impair normal functioning of host proteins, a clear understanding of their 160 impact on cellular mechanisms is critically important. We therefore characterized the 161 interactions of SNX-5422 with the cellular machinery using a physiologically relevant ex 162 vivo human primary tracheobronchial epithelial (TBE) cell model (Mason, 2020) . Fully 163 differentiated human TBE cells from three independent donors (Table S1 ) without known 164 respiratory disease or smoking history were cultured ex vivo at the air-liquid interface. The 165 basolateral side of the cell culture was treated with either 0.1% DMSO (drug-vehicle) or 166 1μM SNX-5422 for 48hrs, followed by bulk RNA sequencing of the total cellular RNA 167 ( Figure 2A ). Principal component analysis of the read counts revealed that treatment with 168 SNX-5422 formed distinct clusters compared to the control group ( Figure S1 ), highlighting 169 differential expression of cellular genes upon drug treatment. Differentially expressed 170 genes (DEGs) between the control group and the SNX-5422-treated group were defined as 171 protein coding genes with a Log2 fold change (FC) ratio > 2 and adjusted p value ≤ 0.001. A 172 volcano plot of the protein coding genes indicated that 1361 genes were differentially 173 expressed between the two groups, with 470 cellular genes being upregulated and 891 174 cellular genes being downregulated upon SNX-5422 treatment ( Figure 2B ). To identify 175 cellular genes whose expression was highly regulated upon SNX-5422 treatment of TBE 176 cells, we collated DEGs with a Log2 FC >6, for which the average normalized read count 177 across donors and experimental conditions was ≥300 (Table S2 ). Using this stringent 178 threshold, we identified 16 cellular genes that were downregulated and 4 cellular genes 179 that were upregulated upon drug treatment ( Figure 2B ). Further categorization of those 180 genes based on functions revealed that SNX-5422-treatment of TBE cells downregulated 181 cytokines and chemokines that serve as chemoattractant for lymphocytes and neutrophils 182 (CCL20, CXCL1), regulators of cellular inflammation (CSF3, S100A8) and proliferation 183 (CDC20), antigen presentation pathway-associated genes ( cytokines resulting in multiple organ failure, ALI and ARDS (Song et al., 2020) . 207 Interestingly, Hsp90 inhibition dampened systemic and pulmonary inflammation and lung 208 injury in a murine model of sepsis (Chatterjee et al., 2007) . Since SNX-5422 exhibited 209 downregulated inflammatory transcriptomic pathways in human TBE cells, we interrogated 210 whether these pathways have been previously associated with SARS-CoV-2 disease 211 progression. To this end, we first selected a gene set whose expression was stringently 212 regulated upon SNX-5422 treatment of human TBE cells (Log2 FC >3, total 287 genes) 213 (Table S2) . We then performed an extensive literature search in PubMed and non-peer 214 reviewed pre-publication repositories to compare our identified gene set with the cellular 215 genes and pathways previously associated with SARS-CoV-2 replication. To maintain 216 physiological relevance, we restricted our literature search to genes and pathways reported 217 in ex vivo SARS-CoV-2-infected primary airway epithelial cells or those identified in blood, 218 bronchioalveolar lavage fluid (BALF) and lung biopsies of SARS-CoV-2 positive patients. 219 Our search identified 55 genes regulated by SNX-5422, which have been associated with 220 SARS-CoV-2 pathogenesis and disease progression. A protein-protein interaction (PPI) 221 network and functional enrichment analysis mapped several of these 55 genes to cellular 222 inflammatory pathways including IL-17 signaling pathway, TNF signaling pathway, cytokine-223 cytokine receptor interaction and chemokine signaling pathway ( Figure 3A ). SNX -5422 224 dampened expression of cellular genes, previously shown to be associated with SARS-225 CoV-2 -mediated proinflammatory response and hyper-cytokinemia ( Figure 3B ). 226 Specifically, these inflammatory genes could be broadly categorized into chemokines 227 (Nunnari et 233 al., 2020), S100A8 (Zhou et al., 2020a) , S100A9 (Zhou et al., 2020a) , SCGB3A1 (Mick et 234 al., 2020) , S100A2 (Xu et al., 2020) ) and interferon-induced proteins (RSAD2 (Zhou et al., 235 2020a) , IFI44L (Mick et al., 2020) , IFITM1 (Zhou et al., 2020a) , MX2 (Lieberman et al., 236 2020), IFI27 (Mick et al., 2020) , ISG15 (Zhou et al., 2020a) ). Collectively, our analysis 237 suggests that early treatment with SNX-5422 may mitigate SARS-CoV-2-mediated 238 hyperinflammation, thereby improving clinical outcomes of COVID-19. In summary, our data support further testing and development of SNX-5422 as an oral 302 post-exposure prophylactic or early-phase therapeutic for SARS-CoV-2 infection. Early 303 administration of SNX-5422 will interfere with SARS-CoV-2 replication machinery and dampen 304 virus-induced inflammation and severe disease outcomes, although human trials and 305 experimental validation of such a mechanism in ex vivo human primary tissue sections or in 306 animal models remains necessary. Additionally, the fact that SNX-5422 is orally bioavailable, 307 and is clinically tested, makes this drug a quality candidate for an easy-to-administer and 308 rapidly translatable post-exposure prophylactic therapy for SARS-CoV-2 infections. Finally, 309 since SNX-5422 targets dependency factors that are utilized by multiple CoVs (Aldeyra with no reported respiratory disease or smoking history (Table S1) (Table S1) differentially expressed genes was generated using 'EnhancedVolcano' package in R, after 514 filtering for described differential expression cutoffs. Heatmaps for differential expression of 515 genes were generated using 'pheatmap' package in R. A vst was applied to count data, and 516 batch corrected with 'limma' package, followed by Z-score normalization. Dot plots 517 demonstrating upregulated and downregulated KEGG pathways were generated using 518 'ClusterProfiler' package in R using a "universe" of all human genes. Protein-protein interaction 519 (PPI) network was constructed using STRING and Cytoscape (vs 3.8.2). 520 521 Biocontainment and biosafety. Work with live SARS-CoV-2 isolate (USA-WA1/2020; BEI 522 Resources NR-52281) was performed under Biosafety Level-3 (BSL-3) in the Duke Regional 523 Biocontainment Laboratory. CCL20 CXCL1 CSF3 S100A8 CXCL5 IL36G CXCL6 CXCL3 RSAD2 CX3CL1 IFI44L IL19 SCGB3A1 CXCL8 S100A9 SPRR2A SPRR2D IFITM1 CXCL2 SAA1 SAA2 IL32 MX2 IFI27 CD14 TNFAIP2 ISG15 S100A2 <-8 Heat shock 591 protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in 592 murine sepsis Association between cytokine profiles and lung injury in COVID-595 19 pneumonia T cell responses in patients with COVID-19 The cytokine 599 storm in COVID-19: An overview of the involvement of the chemokine/chemokine-600 receptor system WHO Declares COVID-19 a Pandemic Serum Proteomics in COVID-19 Patients: Altered Coagulation and Complement Status 606 as a Function of IL-6 Level Identification of Required Host Factors for SARS-CoV-2 611 Infection in Human Cells Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients 618 with COVID-19 pneumonia STAR: ultrafast universal RNA-seq 621 aligner Scale-Up of an Hsp90 Inhibitor Bulk and single-cell gene expression profiling of SARS-CoV-2 631 infected human cell lines identifies molecular targets for therapeutic intervention 638 Application of chemoproteomics to drug discovery: identification of a clinical candidate 639 targeting hsp90 642 Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways 643 activated by the virus, proposes unique sex-specific differences and predicts tailored 644 therapeutic strategies Severe Acute Lung Injury Related to 646 COVID-19 Infection: A Review and the Possible Role for Escin Broad action of Hsp90 as a host chaperone 649 required for viral replication Evolutionary constraints on 651 chaperone-mediated folding provide an antiviral approach refractory to development of 652 drug resistance & 659 KOUTSOUKOU, A. 2020. Complex Immune Dysregulation in COVID-19 Patients with 660 Severe Respiratory Failure A SARS-CoV-2 protein interaction map reveals targets for drug 680 repurposing Matrix 682 metallopeptidase 9 as a host protein target of chloroquine and melatonin for 683 immunoregulation in COVID-19: A network-based meta-analysis Clinical features of patients infected with 2019 novel coronavirus in Wuhan, 688 China SARS-CoV-2 Infection of Pluripotent Stem 694 Cell-derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic 695 Inflammatory Response. bioRxiv Discovery of novel 2-702 aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active 703 antitumor agents Orchestrating high-throughput 709 genomic analysis with Bioconductor Phase I dose-escalation studies of SNX-5422, an orally 713 bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours Lung transcriptome of a COVID-19 patient and systems biology 716 predictions suggest impaired surfactant production which may be druggable by 717 surfactant therapy Drug Repositioning Suggests a Role for the 719 Heat Shock Protein 90 Inhibitor Geldanamycin in Treating COVID-19 Infection Global analysis of 725 protein-RNA interactions in SARS-CoV-2 Ensembl Genomes: an 731 integrative resource for genome-scale data from non-vertebrate species A wrapper tool around Cutadapt and FastQC to consistently apply quality and 734 adapter trimming to FastQ files, with some extra functionality for MspI-digested RRBS-735 type (Reduced Representation Bisufite-Seq) libraries Human coronavirus dependency on host 739 heat shock protein 90 reveals an antiviral target Geldanamycin, a ligand of heat shock 741 protein 90, inhibits the replication of herpes simplex virus type 1 in vitro featureCounts: an efficient general purpose program 744 for assigning sequence reads to genomic features In vivo 748 antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age Differential Expression of Viral Transcripts From 751 Single-Cell RNA Sequencing of Moderate and Severe COVID-19 Patients and Its 752 Implications for Case Severity Moderated estimation of fold change and 754 dispersion for RNA-seq data with DESeq2 Pathogenesis of COVID-19 from a cell biology perspective Nrf2 Activator 758 PB125(R) as a Potential Therapeutic Agent Against COVID-19 Predictors 761 of mortality in patients with COVID-19-a systematic review COVID-19: consider 765 cytokine storm syndromes and immunosuppression Upper airway gene expression differentiates COVID-19 from 771 other acute respiratory illnesses and reveals suppression of Two distinct immunopathological profiles in autopsy 777 lungs of COVID-19 780 Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19) Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic 785 insights into current COVID19 therapies (Review) SARS-coronavirus-2 replication in Vero E6 cells: 793 replication kinetics, rapid adaptation and cytopathology SNX-2112, a selective Hsp90 inhibitor, potently inhibits 797 tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other 798 hematologic tumors by abrogating signaling via Akt and ERK Broncho-alveolar 803 inflammation in COVID-19 patients: a correlation with clinical outcome Corticosteroids in COVID-19 ARDS: Evidence and 806 Hope During the Pandemic A phase I study 810 of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in 811 patients with refractory solid tumor malignancies and lymphomas Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus 815 replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo Hsp90: a key target in HIV infection Cytokine storm induced by SARS-CoV-2 HSP90 at the hub of protein 822 homeostasis: emerging mechanistic insights Pathogenesis of COVID-19-induced ARDS: 824 implications for an ageing population Identification of potential mRNA panels for 826 severe acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment 827 using microarray dataset and bioinformatics methods & 829 SOUNDARARAJAN, V. 2020. Benchmarking evolutionary tinkering underlying human-830 viral molecular mimicry shows multiple host pulmonary-arterial peptides mimicked by 831 SARS-CoV-2 Genetic 836 Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses Transcriptomic characteristics of bronchoalveolar lavage fluid and 847 peripheral blood mononuclear cells in COVID-19 patients The differential immune responses to COVID-19 851 in peripheral and lung revealed by single-cell RNA sequencing SARS coronavirus 7a protein blocks cell cycle progression at G0/G1 854 phase via the cyclin D3/pRb pathway Hsp90: a chaperone for protein folding and gene regulation Neutralizing antibodies for the 863 treatment of COVID-19 Heavy-tailed prior distributions for sequence 865 count data: removing the noise and preserving large differences